Resources

Clinicians and care teams are increasingly focused on GLP‑1 receptor agonists, but SGLT2 inhibitors and metformin in diabetes management remain foundational in achieving comprehensive, evidence‑based outcomes. While GLP‑1 therapies generate headlines for weight loss and glucose control, 2025 guidelines still strongly emphasize the cardioprotective and renoprotective benefits of SGLT2 inhibitors …

Living with type 2 diabetes often means managing more than just blood glucose. For many patients, conditions like cardiovascular disease, chronic kidney disease, or depression take center stage in their care plan. When diabetes isn’t the main problem, how do you keep glucose control on track without compromising treatment for …

For decades, clinicians have relied on A1C as the primary benchmark for diabetes control. Yet many patients and providers now wonder: does a single quarterly number truly reflect daily glucose fluctuations and risks? As continuous glucose monitoring (CGM) becomes more accessible, the metric known as Time in Range (TIR) has …

Could continuous glucose monitoring (CGM) soon become the norm in primary care? Once considered a specialty tool reserved for endocrinologists, CGM is now recommended far earlier in diabetes treatment — even for patients with type 2 diabetes on basal insulin alone. Despite these guideline shifts, primary care adoption has lagged. …

Could the conventional “lifelong treatment” model for type 2 diabetes be rethought? Recent trials suggest that short‑term intensive therapy may offer more than transient glycemic control—it might trigger lasting remission in newly diagnosed patients. Such interventions, combining aggressive pharmacologic therapy or insulin with lifestyle change, show potential to preserve β‑cell …

Could something as simple as a mineral or vitamin really shift the trajectory of type 2 diabetes? It’s a question both patients and clinicians increasingly ask as supplements gain popularity and more studies explore their potential benefits. While standard treatments remain foundational, micronutrients like magnesium and vitamin D have sparked …

When treating patients with diabetes, lifestyle advice such as “eat healthy” and “stay active” is often routine. But what if we took that a step further and issued a formal exercise prescription — in other words, ordering physical activity like we would a drug? Recent research suggests that a structured …

In diabetes care, “therapeutic inertia” refers to the failure to escalate or modify treatment when a patient’s glucose control is suboptimal. Even now — when newer, more effective treatments and monitoring tools are widely available — therapeutic inertia in diabetes remains a stubborn barrier. Providers often wait too long before …

Starting insulin early in the course of type 2 diabetes may seem counter‑intuitive. After all, many patients and clinicians treat insulin as a “last resort.” Yet what if early insulin initiation could actually change the trajectory of the disease — preserving pancreatic function, improving long‑term control, and reducing complications? In …

The class of medications known as GLP-1 receptor agonists — commonly prescribed for type 2 diabetes and increasingly used for weight loss — may offer more than just metabolic benefits. Growing evidence indicates that GLP-1 drugs could play a role in protecting the brain. Could this mean a dual benefit …